Phase II trial of erythropoietin (ErepoXen) in patients with anaemia associated with chronic kidney disease
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2016
Price : $35 *
At a glance
- Drugs Erythropoietin (Primary)
- Indications Anaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Xenetic Biosciences
- 10 Oct 2016 Topline results from cohort 3 published in a Xenetic Biosciences media release.
- 08 Oct 2014 New trial record
- 11 Aug 2014 Tolerability results in the first cohort published in a Xenetic Biosciences media release.